While generally well tolerated, it has some common and rare adverse effects

Reasons: Available immediately Best efficacy among approved options (22.5%) Best tolerability (lowest nausea) Lower cost than Semaglutide Consider Semaglutide if: Insurance covers Wegovy but not Zepbound You prioritize longest safety record Waiting for Retatrutide rarely makes sense: A year or more of delayed treatment Tirzepatide delivers excellent results NOW Conclusion The evolution from single to dual to triple agonist represents remarkable progress: The efficacy progression: Semaglutide (single): 14.9% average weight loss Tirzepatide (dual): 22.5% average weight loss (+51% vs Semaglutide) Retatrutide (triple): 28.7% average weight loss (+93% vs Semaglutide) The mechanism progression: Semaglutide: GLP-1 only Tirzepatide: GLP-1 + GIP Retatrutide: GLP-1 + GIP + Glucagon The tolerability comparison: Semaglutide: 6.9% discontinuation (best retention) Tirzepatide: 6.2% discontinuation (best GI tolerability) Retatrutide: 18.2% discontinuation (highest) The availability reality: Semaglutide & Tirzepatide: FDA-approved, available today Retatrutide: Investigational, not until 2027-2028 For most patients in 2026: Tirzepatide represents the best optionsuperior efficacy (22.5%), excellent tolerability (lowest nausea), lower cost, and immediate availability

Barenbaum said name-brand Ozempic pens allow patients to manually toggle their dose
If you want a broader refresher on safe storage timelines, TrimRx also covers how semaglutide lasts and why refrigeration matters
Additional information Related products BPC-157 5MG (Research Purposes Only) BPC-157 5mg Research Peptide Molecular Formula: CHNO Molecular Weight: 1419.54 g/mol CAS Number: 137525-51-0 Synonyms: Body Protection Compound-157, BPC 157 Purity: 99% (HPLC) Appearance: Lyophilized powder Description: BPC-157 is a synthetic pentadecapeptide that has been examined strictly in laboratory settings for its role in peptide interactions and cellular response mechanisms
doi:10.1016/j.jacc.2025.04.059 Heinsen LJ, Pararajasingam G, Andersen TR, et al